American Journal of Clinical Oncology · 2012 · 30 citations · 2 references
The SBRT combined with gefitinib is a promising treatment strategy for advanced (stage IIIb or IV) NSCLC after the failure of previously chemotherapy. This method improves local control and disease-related symptoms with tolerated toxicity, and even increases the progression-free survival and OS.
2
Targeting the epidermal growth factor receptor in non-small cell lung cancer.
Roy S. Herbst, Paul A. Bunn · PubMed · 2003 · 138 citations
Oncology, Medicine, Pharmacology +13